Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Hutchison China MediTech Limited    HCM   KYG4672N1016

HUTCHISON CHINA MEDITECH LIMITED (HCM)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/09/2018 10/10/2018 10/11/2018 10/12/2018 10/15/2018 Date
4610(c) 4550(c) 4350(c) 4350(c) 4400 Last
1 141 218 25 258 11 555 462 Volume
0.00% -1.30% -4.40% 0.00% +1.15% Change
More quotes
Financials (USD)
Sales 2018 163 M
EBIT 2018 -99,5 M
Net income 2018 -72,3 M
Finance 2018 238 M
Yield 2018 -
Sales 2019 182 M
EBIT 2019 -122 M
Net income 2019 -97,1 M
Finance 2019 118 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 21,9x
EV / Sales2019 20,3x
Capitalization 3 807 M
More Financials
Company
Hutchison China MediTech Ltd. is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products.It operates through the Innovation Platform and Commercial Platform segments.The Innovation Platform segment relates to... 
Sector
Pharmaceuticals
Calendar
02/27Earnings Release
More about the company
Surperformance© ratings of Hutchison China MediTech L
Trading Rating : Investor Rating :
More Ratings
Latest news on HUTCHISON CHINA MEDITECH L
10/05HUTCHISON CHINA MEDITECH : Appointment of HSBC Bank plc as Joint Corporate Broke..
PU
09/19AstraZeneca plots China robot offensive to counter price cuts
RE
09/19AstraZeneca plots China robot offensive to counter price cuts
RE
09/06China unconditionally approves locally discovered, developed drug
AQ
09/05Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treate..
GL
08/07HUTCHISON CHINA MEDITECH : Grant of Share Options under Share Option Scheme
PU
07/27Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical..
GL
07/24HUTCHISON CHINA MEDITECH LIMITED : half-yearly earnings release
07/23HUTCHISON CHINA MEDITECH : Chi-Med Initiates a Phase Ib/II Proof-of-Concept Tria..
PU
07/23Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Sulfatinib in Pancr..
GL
More news
Sector news : Alternative Medicine
10/15AstraZeneca will keep UK investment freeze if no Brexit clarity
RE
10/15AstraZeneca will keep UK investment freeze if no Brexit clarity
RE
10/15BAYER : Could Outsource Some Drug Research -Reuters
DJ
10/15Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit
RE
10/15EUROPEAN PRESS ROUNDUP : Spain Plans Digital Tax, Forecaster Cuts View of U.K. G..
DJ
More sector news : Alternative Medicine
Latest Tweets
10/13Dogs rescued from South Korean meat farm sent to Canada, thanks in part to Si..
149
10/05Breaking news... one of the SEVEN London memorials to Simon Milton has been t..
11
10/05William Boyd talks to Simon Kuper about his African childhood, his unusual wr..
1
10/04William Boyd talks to Simon Kuper about his African childhood, his unusual wr.. 
10/03The latest The #MasterEnergy Daily!  
More tweets
Qtime:535
News from SeekingAlpha
03/12Hutchison China MediTech's (HCM) CEO Christian Hogg on Q4 2017 Results - Earn.. 
03/12Hutchison China Meditech FY2017 revenues up 12%; updates guidance 
03/12Hutchison China Meditech  reports FY results 
03/12JF'S CORE BIOTECH BUYS EDITION 1 VOL : Buying Weakness In 2 Beaten Down Stocks 
03/11WEEK IN REVIEW : China Pharma Deals Top $1.5 Billion For Week 
Chart HUTCHISON CHINA MEDITECH LIMITED
Duration : Period :
Hutchison China MediTech Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HUTCHISON CHINA MEDITECH L
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 53,9 $
Spread / Average Target -5,8%
EPS Revisions
Managers
NameTitle
Christian Hogg Chief Executive Officer & Executive Director
Chi Keung To Chairman
Enrico Magnanelli Vice President & Head-International Operations
Chig Fung Cheng Chief Financial Officer & Executive Director
Wei Guo Su Executive Director, Chief Scientific Officer & EVP
Sector and Competitors
1st jan.Capitalization (M$)
HUTCHISON CHINA MEDITECH LIMITED-22.32%3 830
CANOPY GROWTH CORP118.22%10 824
AURORA CANNABIS INC42.81%9 288
BEIJING TONGRENTANG CO., LTD.-8.10%5 874
DONG-E-E-JIAO CO LTD--.--%4 180
APHRIA INC2.19%3 743